A Phase 2 clinical trial of MRG-106 in mycosis fungoides (MF) patients.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs MRG 106 (Primary)
- Indications Cutaneous T cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 08 Nov 2017 According to a miRagen Therapeutics media release, data from the study is anticipated in 2019/2020.
- 17 Aug 2017 New trial record
- 11 Aug 2017 According to a miRagen Therapeutics media release, company intends to initiate this trial in H2 2018.